Alloc-DOX

• Description :

  Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth[1][2].

• Product Name Alternative :

  N-Alloc doxorubicin

• UNSPSC :

  12352005

• Target :

  AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/alloc-dox.html

• Purity :

  98.40

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(OCC=C)=O

• Molecular Formula :

  C31H33NO13

• Molecular Weight :

  627.59

• References & Citations :

  [1]Miller MA, et al. Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun. 2017 Jul 12;8:15906. |[2]Chen Z, et al. Bioorthogonal catalytic patch. Nat Nanotechnol. 2021 Aug;16 (8) :933-941.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [561022-65-9]